Gilead Sciences Stock Forecast
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 147.10 0.00%
GILD analyst consensus
Consensus (28 analysts)
buy
Avg. price target
$159.27+8.27%
- Strong buy 6
- Buy 16
- Hold 5
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 28 Wall Street analysts covering Gilead Sciences (2026-10-08), 22 rate the stock a buy or strong buy, 5 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $159.27, with a high estimate of $180.00 and a low estimate of $123.00. The average target implies upside of 8.3% from the current price of $147.10.
The spread between the highest and lowest targets is 46.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for GILD.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 6 | 21% |
| Buy | 16 | 57% |
| Hold | 5 | 18% |
| Sell | 0 | 0% |
| Strong sell | 1 | 4% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $123.00 | -16.38% |
| Average target | $159.27 | +8.27% |
| High target | $180.00 | +22.37% |